Buyback yield (TTM)
0.93%
Shareholder yield (TTM)
3.26%
5Y share count change
-0.6%
Buyback spend (TTM)
$1.61B
Cumulative buybacks
$51.21B
Key takeaways
- Gilead Sciences (GILD) repurchased about $1.61B of stock over the trailing twelve months.
- Diluted share count is roughly flat (-0.6%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
- TTM buyback ÷ stock-based-comp ratio of 1.78× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +4.0% per year over the latest 5-year window.
- TTM repurchases used about 26% of free cash flow remaining after dividends.
Dividend & buyback yield over time for Gilead Sciences (GILD)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Gilead Sciences (GILD)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Gilead Sciences (GILD)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Gilead Sciences (GILD)
Latest: $1.92B
Overview
In 2025, Gilead Sciences (GILD) buyback spend totalled $1.92B – surged 67.1% year-over-year.
Through 2020–2025 (5 years), Gilead Sciences buyback spend delivered a +4.0% annualised rate; sustaining 2 straight years of year-over-year growth.
Gilead Sciences buyback spend plunged from $11.00B in 2016 to $1.92B in 2025, a 82.5% drawdown.
The highest annual buyback spend of $11.00B was reported in 2016. The lowest in the available history was $0.00 in 1990.
Gilead Sciences Buyback Spend 2025: $1.92B
Gilead Sciences posted buyback spend of $1.92B in 2025, surged 67.1% from 2024.
Gilead Sciences Buyback Spend 2024: $1.15B
In 2024, Gilead Sciences reported buyback spend of $1.15B, grew 15.0% from 2023.
Gilead Sciences Buyback Spend 2023: $1.00B
Gilead Sciences buyback spend in 2023 was $1.00B, declined 28.4% below 2022.
Gilead Sciences Buyback Spend 2022: $1.40B
2022's buyback spend for Gilead Sciences came in at $1.40B, surged 155.7% from 2021.
Gilead Sciences Buyback Spend 2021: $546.00M
Gilead Sciences buyback spend in 2021 was $546.00M.
See more financial history for Gilead Sciences (GILD).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $1.92B | $894.00M | $1.03B | 1.26% | 1.25B | 0.0% | |
| 2024 | $1.15B | $835.00M | $315.00M | 1.00% | 1.25B | -0.2% | |
| 2023 | $1.00B | $766.00M | $234.00M | 0.99% | 1.26B | -0.3% | |
| 2022 | $1.40B | $644.00M | $752.00M | 1.30% | 1.26B | 0.0% | |
| 2021 | $546.00M | $635.00M | −$89.00M | 0.60% | 1.26B | -0.1% | |
| 2020 | $1.58B | $643.00M | $940.00M | 2.17% | 1.26B | -1.1% | |
| 2019 | $1.75B | $636.00M | $1.11B | 2.13% | 1.28B | -2.4% | |
| 2018 | $2.90B | $845.00M | $2.06B | 3.59% | 1.31B | -0.8% | |
| 2017 | $954.00M | $638.00M | $316.00M | 1.02% | 1.32B | -2.9% | |
| 2016 | $11.00B | $380.00M | $10.62B | 11.67% | 1.36B | -10.7% | |
| 2015 | $10.00B | $382.00M | $9.62B | 6.88% | 1.52B | -7.7% | |
| 2014 | $5.35B | $360.00M | $4.99B | 3.77% | 1.65B | -2.8% | |
| 2013 | $582.00M | $252.00M | $330.00M | 0.51% | 1.69B | +7.1% | |
| 2012 | $667.00M | $209.00M | $458.00M | 1.20% | 1.58B | +0.1% | |
| 2011 | $2.38B | $192.38M | $2.19B | 7.89% | 1.58B | -9.5% | |
| 2010 | $4.02B | $200.04M | $3.82B | 13.73% | 1.75B | -6.5% | |
| 2009 | $998.50M | $180.68M | $817.81M | 2.56% | 1.87B | -2.6% | |
| 2008 | $1.97B | $153.36M | $1.82B | 4.23% | 1.92B | -0.6% | |
| 2007 | $487.54M | $0.00 | $487.54M | 1.14% | 1.93B | +5.0% | |
| 2006 | $544.94M | $0.00 | $544.94M | 1.84% | 1.84B | -3.2% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 1.90B | +2.2% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 1.86B | +15.4% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 1.61B | -2.6% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 1.65B | +2.1% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 1.62B | +11.1% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 1.46B | +6.3% | |
| 1999 | $0.00 | $0.00 | $0.00 | — | 1.37B | +4.4% | |
| 1998 | $0.00 | $0.00 | $0.00 | — | 1.31B | +26.2% | |
| 1997 | $0.00 | $0.00 | $0.00 | — | 1.04B | +17.0% | |
| 1996 | $0.00 | $0.00 | $0.00 | — | 0.89B | — | |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — | |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
- 2025$1.92B
- 2024$1.15B
- 2023$1.00B
- 2022$1.40B
- 2021$546.00M
- 2020$1.58B
- 2019$1.75B
- 2018$2.90B
- 2017$954.00M
- 2016$11.00B
- 2015$10.00B
- 2014$5.35B
- 2013$582.00M
- 2012$667.00M
- 2011$2.38B
- 2010$4.02B
- 2009$998.50M
- 2008$1.97B
- 2007$487.54M
- 2006$544.94M
- 2005$0.00
- 2004$0.00
- 2003$0.00
- 2002$0.00
- 2001$0.00
- 2000$0.00
- 1999$0.00
- 1998$0.00
- 1997$0.00
- 1996$0.00
- 1995$0.00
- 1994$0.00
- 1992$0.00
- 1991$0.00
- 1990$0.00
Buybacks vs stock-based compensation for Gilead Sciences (GILD)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 1.78×.
Buybacks vs dividends (share of cash returned) for Gilead Sciences (GILD)
How Gilead Sciences splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Gilead Sciences, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $216.35M | |
| $0.00 | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $216.35M
- $0.00
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $6.20B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation